Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 7:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Healthy Male and Female Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function

NCT01240967
View directory record Official record
Conditions
Healthy Volunteers, Patients, Pharmacokinetics, Renal Impairment
Interventions
TC-5214
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 16, 2014 · Synced Jun 10, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117

NCT03325595
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AEF0117, Placebo
Drug
Lead sponsor
Aelis Farma
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Jun 10, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioavailability Study of FL-101 in Healthy Male and Female Subjects

NCT04983732
View directory record Official record
Conditions
Healthy Subjects
Interventions
FL-101-Intravenous, FL-101-Subcutaneous
Drug
Lead sponsor
Flame Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Jun 10, 2026, 7:30 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

GSK1247303 First Time in Human Study

NCT00651079
View directory record Official record
Conditions
Healthy Subjects
Interventions
GSK1247303
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2010 · Synced Jun 10, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study in Healthy People to Test How 2 Different Formulations of BI 695501 Are Taken up by the Body When Given as an Injection

NCT05203289
View directory record Official record
Conditions
Healthy
Interventions
BI 695501 - higher concentration, BI 695501 - lower concentration
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 55 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Miami, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Jun 10, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Investigate the Safety and Tolerability of TC-5214 Following Oral Administration of Multiple Doses for up to 8 Days

NCT01145768
View directory record Official record
Conditions
Healthy
Interventions
TC-5214, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2010 · Synced Jun 10, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety and Tolerability of AGO178C in Subjects With Renal Deficiencies Compared With Healthy Subjects

NCT01459250
View directory record Official record
Conditions
Renal Impairment
Interventions
AGO178C
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 79 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Jun 10, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects

NCT00914667
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
warfarin, Warfarin plus Fesoterodine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 31, 2011 · Synced Jun 10, 2026, 7:30 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Blood Flow Restriction (BFR) Training on the Ulnar Collateral Ligament (UCL)

NCT06664827
View directory record Official record
Conditions
Healthy, Healthy Male and Female Subjects, Healthy Volunteers
Interventions
Delfi PTS Blood Flow Restriction Tourniquet System
Device
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Jun 10, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State

NCT01930006
View directory record Official record
Conditions
Advanced Malignancies
Interventions
MGCD265
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Jun 10, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability and Pharmacokinetics (PK) (Including Food Effect) of Oral Doses of AZD5847 in Healthy Volunteers

NCT01037725
View directory record Official record
Conditions
Healthy
Interventions
AZD5847, Placebo to AZD5847
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2010 · Synced Jun 10, 2026, 7:30 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects

NCT04909723
View directory record Official record
Conditions
Healthy Volunteers, Enteric Hyperoxaluria
Interventions
NOV-001, NB1000S, NB2000P, Placebo
Combination Product · Biological · Drug
Lead sponsor
Novome Biotechnologies Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Daytona Beach, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Jun 10, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of VS 105

NCT03043482
View directory record Official record
Conditions
Chronic-kidney Disease Stage 5D on Stable Hemodialysis
Interventions
Single VS-105/placebo to healthy, Multiple VS-105/placebo to healthy, Multiple VS-105/placebo to HD subjects
Drug
Lead sponsor
Vidasym, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 6, 2019 · Synced Jun 10, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

JNJ-41443532 Sex, Race, and Age Pharmacokinetic (PK) Study

NCT01105780
View directory record Official record
Conditions
Healthy
Interventions
Placebo, JNJ-41443532
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Jun 10, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011

NCT02431481
View directory record Official record
Conditions
Normal Renal Function, Impaired Renal Function
Interventions
LEE011
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jun 10, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function

NCT03192111
View directory record Official record
Conditions
Renal Impairment, Healthy Volunteer
Interventions
Entinostat
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Jun 10, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects

NCT02022748
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
ticagrelor
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Lakewood, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Jun 10, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AZD7325 Multiple Ascending Dose Study

NCT00681915
View directory record Official record
Conditions
Healthy Volunteer
Interventions
AZD7325
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2010 · Synced Jun 10, 2026, 7:30 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers

NCT01044108
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
NNC 0070-0002-0453, '2-0453, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Jun 10, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects

NCT03836599
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Verinurad, Allopurinol, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 12, 2019 · Synced Jun 10, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate The Metabolism And Excretion Of 14C SB-751689 Given To Healthy Males And Postmenopausal Women

NCT00499928
View directory record Official record
Conditions
Osteoporosis
Interventions
SB-751689
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
35 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 17, 2009 · Synced Jun 10, 2026, 7:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Cycling, Running, and Playing Rugby on Three Biomarkers That May Indicate Brain Injury

NCT06804291
View directory record Official record
Conditions
Healthy Male and Female Subjects
Interventions
Running, Cycling, Rugby, control group
Other
Lead sponsor
Appalachian State University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boone, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Jun 10, 2026, 7:30 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of FB-001 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria

NCT05650112
View directory record Official record
Conditions
Healthy, Enteric Hyperoxaluria
Interventions
FB-001, Placebo
Biological
Lead sponsor
Federation Bio Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 24, 2023 · Synced Jun 10, 2026, 7:30 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of JPH034 in Healthy Adult Participants

NCT07534657
View directory record Official record
Conditions
Health Adult Subjects
Interventions
JPH034, Placebo Control
Drug · Other
Lead sponsor
J-Pharma Co., Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jun 10, 2026, 7:30 AM EDT